For newly diagnosed CLL patients, 63.16% of respondents were very likely to order TP53 testing, 71.06% to order del(17p) testing, and 68.42% to order IgHV mutation analysis. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.